An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Completed
Ferring Pharmaceuticals
Phase 2/Phase 3
2005-02-01
This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was
to be treated until he was discontinued or withdrawn from the study, or a marketing
authorization for degarelix had been obtained.
The study was terminated when all ongoing participants had been treated for at least 5 years
(including one year in the main study).
A Trial of Degarelix in Patients With Prostate Cancer
Completed
Ferring Pharmaceuticals
Phase 3
2009-06-01
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of
degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in
patients with prostate cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
